Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum...
M. Camilli, M. Ortenzi, L. Leo et al.· Journal of Cardiovascular Ph...· 0 citations
Heart failure (HF) is traditionally characterized by hemodynamic impairment and neurohormonal activation, with congestion representing a central clinical feature. However, the electrophysiological consequences of congestion remain underexplored. Emerging evidence suggests that volume overload and elevated filling press...
E. Salerno, I. Fumarulo, Claudia Mendicino et al.· Current problems in cardiolo...· 0 citations
The HFA-ICOS score effectively stratifies mortality and cardiotoxicity risk among R-COMP–treated patients and supports its application in routine treatment of lymphomas requiring anthracycline-based therapy.
M. Camilli, I. Torre, L. Leo et al.· European Heart Journal, Supp...· 0 citations
Overall, Lp(a) should be regarded as both a meaningful biomarker and a promising therapeutic target, although ongoing outcome trials are needed to determine whether selective Lp(a) lowering translates into clinical benefit across interventional cardiovascular settings.
F. M. Animati, Simone Proietti, Francesco Auletta et al.· Journal of Clinical Medicine· 0 citations
The observed HF-cancer association is influenced by statistical methodology, shared risk factors, differences in surveillance intensity and cancer type, that confound analyses investigating possible causal biological links.
L. Sanasi, A. Iaconelli, Danila Azzolina et al.· European Journal of Heart Fa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
